Rosetta Genomics Posts Higher R&D Costs, Widened Loss in Q2; Inks Co-Development Pact with Ben Gurion University | GenomeWeb
NEW YORK (GenomeWeb News) - Rosetta Genomics today reported no second-quarter revenues, accompanied by a 55 percent rise in R&D spending and a 27 percent increase in net loss.
 
R&D spending for the three months ended June 30 increased to $1.7 million from $1.1 million in the year-ago period.
 
Net loss increased to $2.3 million from $1.8 million in the second quarter of 2005.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.